Joan Barrot

Dr. Joan Barrot

orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 February 2013 in BMC Nephrology
Verified
Journal Article
Open access
PDF file
ARAntonio Rodriguez-Poncelas
Antonio Rodriguez-Poncelas
JGJosep Garre-Olmo
Josep Garre-Olmo
JFJosep Franch-Nadal
Josep Franch-Nadal
JDJavier Diez-Espino
Javier Diez-Espino
XMXavier Mundet-Tuduri
Xavier Mundet-Tuduri
RGRedGDPS Study Group
RedGDPS Study Group
Bakground: The objective of this study was to determinate the prevalence of chronic kidney disease (CKD) and the different stages of CKD in patients with type 2 diabetes mellitus (DM2) treated in primary care consults in Spain. Methods: A national cross-sectional study was performed in primary care consults. The following data were collected: demographic and anthropometric information; list of present cardiovascular risk factors (CVRF); previous macrovascular and microvascular disease history; physical examination and analytical data from the previous 12 months, including the urine albumin-creatinine ratio (UACR) and estimated glomerular filtration rate (eGFR) to evaluate renal function. Results: With regard to the patients, 27.9% presented some degree of CKD as follows: 3.5% with stage 1; 6.4% with stage 2; 16.8% with stage 3 (11.6% with stage 3A and 5.2% with stage 3B); and 1.2% with stages 4 and 5. The prevalence of patients with UACR ≥ 30 mg/g was 15.4% (13% microalbuminuria and 2.4% macroalbuminuria). Renal impairment (RI) was found in 206 patients (18%) of whom 133 patients (64.6%) was stage 3A, 60 patients (29.1%) was stage 3B and 13 patients (6.3%) stages 4 and 5. Among patients with RI, 143 patients (69.4%) had normoalbuminuria. The following variables were significantly associated with CKD: age; sex (women); systolic arterial blood pressure (SABP) ≥ 150 mmHg; and a previous history of cardiovascular disease. Conclusions: The results showed that the prevalence for any type of CKD was 27.9%. A systematic determination of UACR and eGFR may contribute to an early diagnosis, thus allowing intervention during the initial stages of the disease when treatment is more efficient.

23 November 2024 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
CHCarlos Hernández-Teixidó
Carlos Hernández-Teixidó
JBJoan Barrot
Joan Barrot
SJSònia Miravet Jiménez
Sònia Miravet Jiménez
BFBerta Fernández-Camins
Berta Fernández-Camins
Didac MauricioDidac Mauricio
Didac Mauricio
JFJosep Franch-Nadal
Josep Franch-Nadal
Background/Objectives: This study aimed to assess the incidence of diabetic retinopathy (DR) in patients with type 2 diabetes (T2DM) treated in primary-care settings in Catalonia, Spain, and identify key risk factors associated with DR development. Methods: A retrospective cohort study was conducted using the SIDIAP (System for Research and Development in Primary Care) database. Patients aged 30–90 with T2DM who underwent retinal screening between 2010 and 2015 were included. Multivariable Cox regression analysis was used to assess the impact of clinical variables, including HbA1c levels, diabetes duration, and comorbidities, on DR incidence. Results: This study included 146,506 patients, with a mean follow-up time of 6.96 years. During this period, 4.7% of the patients developed DR, resulting in an incidence rate of 6.99 per 1000 person-years. Higher HbA1c levels were strongly associated with an increased DR risk, with patients with HbA1c > 10% having more than four times the risk compared to those with HbA1c levels < 7% (hazard ratio: 4.23; 95% CI: 3.90–4.58). Other significant risk factors for DR included greater diabetes duration, male sex, ex-smoker status, macrovascular disease, and chronic kidney disease. In contrast, obesity appeared to be a protective factor against DR, with an HR of 0.93 (95% CI: 0.89–0.98). Conclusions: In our real-world setting, the incidence rate of DR was 6.99 per 1000 person-years. Poor glycemic control, especially HbA1c > 10%, and prolonged diabetes duration were key risk factors. Effective management of these factors is crucial in preventing DR progression. Regular retinal screenings in primary care play a vital role in early detection and reducing the DR burden for T2DM patients.

22 October 2023 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
PRPedro ROMERO-AROCA
Pedro ROMERO-AROCA
RVRaquel Verges
Raquel Verges
JPJordi Pascual-Fontanilles
Jordi Pascual-Fontanilles
Aida VallsAida Valls
Aida Valls
JFJosep Franch-Nadal
Josep Franch-Nadal
BMBaget-Bernaldiz Marc
Baget-Bernaldiz Marc
(1) Background: Diabetic retinopathy (DR) remains the leading cause of low vision and blindness in young adults of working age. Although the most important risk factors—such as the duration of diabetes mellitus (DM) and glycemic control measured by HbA1c—are known, the effects of lipids are not as clear. The aim of the present study is to analyze the effects of lipids on the development of DR. (2) Methods: This is a retrospective study of a population of 175,645 DM2 patients, during the period 2010 to 2020, in which the effects of different lipid factors are studied. (3) Results: The variables that most influenced the development of DR in our study, based on significance and cumulative hazard (CH), were arterial hypertension (CH 1.217, p < 0.001), HbA1c levels (CH 1.162, p = 0.001), microalbuminuria (CH 1.012, p < 0.001), LDL-C cholesterol (CH 1.007, p = 0.012), TC/HDL-C index (CH 1.092, p < 0.001), No-HDL-C/HDL-C index (CH 1.065, p = 0.002), the use of statins (CH 1.001, p = 0.005), and body mass index (CH 1.007, p < 0.001). (4) Conclusions: LDL-cholesterol, TC/HDL-C, and No-HDL-C/HDL-C indices are related to the development of DR, and there is a protective effect of HDL-cholesterol and the use of fibrates.

1 January 2022 in Diabetes práctica
Verified
Journal Article
Closed access
JBJoan Barrot
Joan Barrot
Según el Consejo Superior de Investigaciones Científicas, la medicina de precisión corresponde a un enfoque para el tratamiento y la prevención de enfermedades que tiene en cuenta la variabilidad individual en los genes, el entorno y el estilo de vida de cada persona; este tipo de medicina busca ofrecerle a cada paciente un tratamiento absolutamente personalizado, con base en la integración de los datos genómicos (el reconocimiento de su genética particular) y de otras ciencias ómicas con el conjunto de datos clínicos del paciente y su ambiente, lo que permite una práctica clínica adaptada a las características individuales de cada sujeto. Además, un aspecto clave que contempla esta nueva medicina es la de un diagnóstico de precisión, que implica mejorar la caracterización del diagnóstico de la diabetes mellitus para la optimización terapéutica o para mejorar la claridad pronóstica. Este proceso puede implicar la subclasificación del diagnóstico en subtipos o la utilización de algoritmos probabilísticos que ayudan a refinar un diagnóstico sin categorización.

5 January 2026 in Atencion Primaria
Verified
Journal Article
Open access
MMMaria Miñana-Castellanos
Maria Miñana-Castellanos
MGMaria Ramon Granés
Maria Ramon Granés
BCBerta Fernández Camins
Berta Fernández Camins
EMElena Navas Méndez
Elena Navas Méndez
JBJoan Barrot
Joan Barrot
CECarolina Lapena Estella
Carolina Lapena Estella
To describe the population with type 2 diabetes mellitus (T2DM) meeting frailty criteria and assess their management based on clinical guidelines (CGL). Patient characteristics, prescribed treatments, adherence to recommendations, and overtreatment prevalence were analyzed. Cross-sectional observational study using retrospective data. SIDIAP database (primary care records, Catalonia, Spain). 594,777 T2DM patients; other diabetes types were excluded. Sociodemographic, clinical, and treatment characteristics were assessed. Frailty was defined using consensus criteria as the presence of one or more major criteria or two or more minor criteria. Major criteria were defined as a Charlson index>4, a Barthel index 75 years, MEDEA U4 or U5, established cardiovascular disease, and chronic kidney disease. Medications were classified as indicated or not recommended, based on CGL. Not recommended treatments included insulin and sulfonylureas due to their hypoglycemia risk. Glycemic control (HbA1c) and inappropriate treatments in frail patients were examined. Overtreatment was defined as use of not recommended treatments in patients with correct metabolic control (HbA1c<7%). A total of 22.8% of individuals with T2DM met clinical criteria for frailty. Sulfonylureas were the second most frequently prescribed class of glucose-lowering agents after metformin across all groups. Among frail patients, 14% were treated with therapies not recommended by clinical guidelines, primarily insulin (39.4%) and sulfonylureas (29.2%). Overtreatment was observed in over 20% of frail individuals. Almost 1 every 4 people with T2DM meet frailty criteria. Low adherence to guidelines and a high prevalence of inappropriate treatments and overtreatment were observed. These findings emphasize the need for increased awareness and better guideline implementation to improve care for this vulnerable population.

20 February 2026 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
ÓMÓscar Martínez-Pérez
Óscar Martínez-Pérez
SLSeila Lorenzo-Herrero
Seila Lorenzo-Herrero
EAEster Amado-Guirado
Ester Amado-Guirado
FGFernando Gomez-Peralta
Fernando Gomez-Peralta
JBJesús Balea-Filgueiras
Jesús Balea-Filgueiras
MCMónica Cerezales
Mónica Cerezales
Background: Type 2 diabetes (T2D) is associated with acute and chronic complications, entailing significant use of healthcare resources. Clinical guidelines recommend holistic management and recognize the critical role of obesity and cardio-renal protection in T2D. This study aims to estimate the clinical, quality of life, and economic benefits of optimized weight, metabolic, and cardiovascular management of T2D-related complications in Spain. Methods: An estimation model was built incorporating the risk of complications associated with changes in glycated hemoglobin (HbA1c), weight and high-sensitivity C-reactive protein (hs-CRP), considering incidence of complications and healthcare costs in Spain. A literature review was performed to identify these clinical inputs. The potential reduction in the annual number of complications and their associated disability-adjusted life years (DALYs) and costs were estimated for reductions of 1% HbA1c, 5% weight and 0.5 mg/L hs-CRP in three T2D patient subgroup scenarios. Probabilistic sensitivity analyses were conducted to validate the results and determine their potential range. Results: Combined reduction of HbA1c, weight and hs-CRP was estimated to prevent 19.16–20.80% T2D complications per year. This led to an estimated range of 1317–6568 avoided DALYs, and potential annual savings between €242.77M and €821.68M depending on the T2D patient subgroup. Savings per patient and year ranged from €196.86 to €296.75 for the three scenarios analyzed. Sensitivity analysis validated these results. Conclusions: Integrated management of patients with T2D, controlling HbA1c levels, weight, and cardiovascular benefit, can improve patient outcomes, reduce incidence of complications, prevent quality of life worsening, and result in cost savings for the Spanish national healthcare system.